These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1312 related articles for article (PubMed ID: 29518562)

  • 41. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
    Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
    Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.
    Schiffman M; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Apple R; Aldrich C; Erlich HA; Tam T; Befano B; Burk RD; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1304-10. PubMed ID: 26088703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV detection in a self-collected vaginal swab combined with VIA for cervical cancer screening with correlation to histologically confirmed CIN.
    Kamal EM; El Sayed GA; El Behery MM; El Shennawy GA
    Arch Gynecol Obstet; 2014 Dec; 290(6):1207-13. PubMed ID: 25009070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of HPV16/18 in Triage of Cytological Atypical Squamous Cells of Undetermined Significance.
    Cao X; Liu S; Jia M; Chen H; Zhao D; Dong B; Guo Z; Ren L; Zhang S; Sun X
    Anal Cell Pathol (Amst); 2019; 2019():4324710. PubMed ID: 31934532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening.
    Wei B; Mei P; Huang S; Yu X; Zhi T; Wang G; Xu X; Xiao L; Dong X; Cui W
    Virol J; 2020 Nov; 17(1):171. PubMed ID: 33168022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2.
    Pajtler M; Milicić-Juhas V; Milojković M; Topolovec Z; Curzik D; Mihaljević I
    Coll Antropol; 2010 Mar; 34(1):81-6. PubMed ID: 20432737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of cervical cancer screening models based on Pap and HPV tests in Tbilisi, Georgia.
    Kiguradze E; Skhirtladze T; Chkhartishvili N; Gogoladze T; Chikhladze N; Alibegashvili T
    Cent Eur J Public Health; 2024 Sep; 32(3):166-172. PubMed ID: 39352091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa.
    Dreyer G; Maske C; Stander M
    PLoS One; 2019; 14(9):e0221495. PubMed ID: 31509545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology.
    Einstein MH; Garcia FA; Mitchell AL; Day SP
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1185-9. PubMed ID: 21527581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.